STOCK TITAN

First Light, Mathew Arens report 10.8% stakes in Neogenomics (NEO)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Neogenomics, Inc. amendment filing reports that First Light Asset Management, LLC beneficially owns 13,631,016 shares (10.47%) and Mathew P. Arens beneficially owns 14,093,416 shares (10.82%). The filing is a joint Schedule 13G/A stating shared voting and dispositive power for the Manager and Mr. Arens.

Positive

  • None.

Negative

  • None.
First Light shares beneficially owned 13,631,016 shares Amount reported in Item 4 for First Light Asset Management, LLC
First Light percent of class 10.47% Percent of class reported in Item 4 for First Light
Mathew P. Arens shares beneficially owned 14,093,416 shares Amount reported in Item 4 for Mathew P. Arens
Mathew P. Arens percent of class 10.82% Percent of class reported in Item 4 for Mathew P. Arens
Sole voting power (Arens) 200,000 shares Sole power to vote reported for Mathew P. Arens in Item 4
Filing signature date 05/07/2026 Execution dates for signatures on the amendment
Schedule 13G/A regulatory
"Jointly filed Amendment No. 1 reporting beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficial owner regulatory
"The Manager may be deemed to be the beneficial owner of 13,631,016 of the Issuer's shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared dispositive power regulatory
"Shared Dispositive Power 13,631,016.00 reported for the Manager"
joint filing agreement regulatory
"Exhibit A: Joint Filing Agreement"





64049M209

(CUSIP Number)
04/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



First Light Asset Management, LLC
Signature:/s/ Kurt T. Peterson
Name/Title:Kurt T. Peterson/Chief Compliance Officer
Date:05/07/2026
Mathew P. Arens
Signature:/s/ Mathew P. Arens
Name/Title:Mathew P. Arens/Chief Executive Officer
Date:05/07/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

FAQ

What does Neogenomics (NEO) Schedule 13G/A amendment show?

It reports ownership stakes: First Light holds 13,631,016 shares (10.47%) and Mathew P. Arens holds 14,093,416 shares (10.82%). The filing lists shared voting and dispositive power and is a joint declaration under Section 13(d).

Who is filing the Schedule 13G/A for NEO?

The filing is jointly made by First Light Asset Management, LLC and Mathew P. Arens. The Manager advises separate accounts and private funds; Mr. Arens is managing member and majority owner and also holds shares directly and in a joint account.

How much voting control is reported in the NEO filing?

The filing shows shared voting power of 13,631,016 shares for First Light and 13,893,416 shares for Mr. Arens, with sole voting power of 200,000 shares held directly by Mr. Arens as disclosed in Item 4.

Does the Schedule 13G/A state who receives proceeds or dividends for NEO shares?

It states the Manager advises accounts that have the right to receive dividends or proceeds, but does not allocate proceeds details; the Manager and Mr. Arens report beneficial ownership and shared dispositive power for the cited share amounts.

When was the Schedule 13G/A signed for Neogenomics (NEO)?

The signatures on the amendment show execution dates of 05/07/2026 by Kurt T. Peterson (Chief Compliance Officer) and 05/07/2026 by Mathew P. Arens (Chief Executive Officer) as indicated in the filing.